Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics presented extended follow-up data from its pivotal Phase 3 trial of aglatimagene in localized prostate cancer at the AUA 2026 Annual Meeting. The data confirmed a statistically significant 39% improvement in disease-free survival (HR 0.61, p=0.0031) in the intention-to-treat population after a median follow-up of 58 months. In the intermediate-risk subgroup, which comprised 85% of patients, the treatment showed a 90% reduction in time to metastasis and a 41% improvement in disease-free survival, reinforcing the asset's potential to reduce recurrence and metastatic risk.
Key figures
- Drug Name
- aglatimagene besadenovec (CAN-2409)
- Phase Of Trial
- Phase 3
- Dfs p value itt
- 0.0031
- Dfs improvement itt
- 39%
- Dfs hazard ratio itt
- 0.61
- Bla submission target
- Q4 2026
- Median follow up months
- 58
- Total patients enrolled
- 745
- Dfs improvement intermediate risk
- 41%
- Ttm improvement intermediate risk
- 90%
- Ttm hazard ratio intermediate risk
- 0.1
- Metastasis rate placebo intermediate
- 2.35%
- Metastasis rate treatment intermediate
- 0.24%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.